




## ASO Visual Abstract: The New Normal? Patient Satisfaction and Usability of Telemedicine in Breast Cancer Care


Bryan A. Johnson, BS<sup>1</sup>, Bruce R. Lindgren, MS<sup>2</sup>, Anne H. Blaes, MD<sup>3</sup>, Helen M. Parsons, PhD, MPH<sup>4</sup>, Christopher J. LaRocca, MD<sup>5</sup>, Ronda Farah, MD<sup>6</sup>, and Jane Yuet Ching Hui, MD, MS<sup>5</sup> 

<sup>1</sup>University of Minnesota Medical School, Minneapolis, MN; <sup>2</sup>Masonic Cancer Center, University of Minnesota, Minneapolis, MN; <sup>3</sup>Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN; <sup>4</sup>Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN; <sup>5</sup>Division of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN; <sup>6</sup>Department of Dermatology, University of Minnesota, Minneapolis, MN

### SUMMARY

The COVID-19 pandemic brought about a sudden adoption of telemedicine for ambulatory patient care. We conducted an anonymous survey of adult breast cancer patients regarding patient satisfaction and usability of telemedicine after breast cancer-specific oncology visits using a modified Telehealth Usability Questionnaire (<https://doi.org/10.1245/s10434-021-10448-6>). Overall, respondents were satisfied (median overall patient satisfaction score 5.5 out of 7) and found telemedicine to be usable (median overall telemedicine usability score 5.6 out of 7). This is irrespective of patient age, race, location of residence, insurance status, previous visit commute time, oncology specialty seen, prior telemedicine visits, or whether patients were actively receiving cancer treatment. Telemedicine may have a continued role in future ambulatory breast cancer care.

[org/10.1245/s10434-021-10448-6](https://doi.org/10.1245/s10434-021-10448-6)). Overall, respondents were satisfied (median overall patient satisfaction score 5.5 out of 7) and found telemedicine to be usable (median overall telemedicine usability score 5.6 out of 7). This is irrespective of patient age, race, location of residence, insurance status, previous visit commute time, oncology specialty seen, prior telemedicine visits, or whether patients were actively receiving cancer treatment. Telemedicine may have a continued role in future ambulatory breast cancer care.



**FUNDING** This study was supported in part by the National Institutes of Health’s National Center for Advancing Translational Sciences, Grant UL1TR002494. This research was also supported in part by the National Cancer Institute P30 Cancer Center Support Grant, Grant CA77598, of Masonic Cancer Center, University of Minnesota. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**DISCLOSURES** The authors have no conflicts of interest to declare.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.